Bentley joined CTTC in June 2011 and is responsible for directing all aspects of the office, focusing on faculty service and transactional efficiency. Prior to Vanderbilt, Bentley served for five years as the director of commercialization for Cleveland Clinic Innovations, that health care center’s technology commercialization function. Before the Cleveland Clinic, he served as the associate director of the University of Virginia’s Patent Foundation. Bentley received his M.S.
Mary Albertson is responsible for directing the team that manages intellectual property created at Georgia Tech. She is an internationally recognized leader in the field of technology transfer. For most of her career, she was with Stanford University, where she culminated her 26 years there as Associate Director of Operations for the Office of Technology Licensing.
Moderator: Chris Sloan - Shareholder, Baker Donelson
Hear from the innovative leaders who are transforming how the “modern” university or national lab prepares their most disruptive technologies for venture capital investment.
Speakers:
Todd is the Associate Vice President of Research and Executive Director for the office. He leads the team who focus on creating value from intellectual property developed by Emory researchers. Todd has worked extensively with researchers to translate their promising scientific and medical discoveries into new products that benefit society. This crucial activity helps assure that research is translated into practical applications, including new life-saving medical products that benefit the public who helped to fund it.
Chris Sloan is the co-chair of the Firm’s Emerging Companies and Venture Capital Group, focusing on corporate structure and governance, venture capital financings, M&A, contract law, and IP protection for early-stage, high-growth businesses. He advises technology and healthcare companies on complex IT transactions and emerging technologies like AI, digital health, and blockchain.
Dr. Charleson S. Bell, PhD is a modern day polymath, pioneering and drawing from multiple fields and bodies of knowledge to solve many of the world's current problems. A multi-talented man of Faith, Dr. Bell not only excels in Innovation and Research but also the arts including Creative Writing and Music/Film Production. Unifying and uplifting others, either through innovation or art, is his passion.
We fix the supply chain for metal parts by developing more efficient (cheaper, cleaner, faster) manufacturing processes based on lost foam investment casting and 3D printing.
David Blittner is chair of the private equity transactions group and a partner in the New York office. David is a seasoned corporate transactions attorney with over 30 years of experience practicing in New York. He advises private equity sponsors in connection with acquisitions, dispositions and financings. He has deep experience steering leveraged buyouts and dispositions of public and private companies, as well as minority investments, public recapitalizations and restructurings.
As founder and CEO of ZIRUS, David oversaw the development of a host based antiviral drug platforms. David was the Head of the Biotechnology Patent Group at Needle & Rosenberg as the group rose to national prominence through its association with the NIH, NIAID, and the CDC. He was also a co-founder of Georgia Venture Partners and a co-founder and member of the Board of Directors at Maxia Pharmaceuticals, where he directed the strategy of the drug patent portfolio before it was acquired by Incyte Pharmaceuticals.
